NCT05947123Completed
Real-life Study of the Efficacy of Management of Migraine Patients After Failure of 2 Prophylactic Treatments
Real-life Study of the Efficacy of Management of Migraine Patients After Failure of 2 Prophylactic Treatments: a Retrospective Study
Source: ClinicalTrials.gov · Last updated 9 Aug 2024
Brief summary (registry, in English)
This is a real-life, observational, single-center cohort study to describe the efficacy of prophylactic treatment in patients after failure of at least 2 prophylactic treatments. Patients included in the study will be followed up in consultations or day hospitals according to their usual care, and will be asked to complete the MIgraine Disability Assessment (MIDAS), Headache Impact Test short-form (HIT-6), Patient Global Impression of Change (PGIC), Hospital Anxiety and Depression (HAD) scale and Work and Personal Activities Impairment (WPAI) questionnaires at each visit. Data describing their care will be extracted from computerized patient records.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 127 (actual)
- First submitted
- 7 Jul 2023
- Start date
- 1 Jun 2023
- Primary completion date
- 1 Mar 2024
- Lead sponsor
- Centre Hospitalier Régional Metz-Thionville
- Diseases
- Migraine
- NCT number
- NCT05947123
What you commit to
- Study type: Observational
- Participants enrolled: 127
- From 1 Jun 2023 to the primary completion date, 1 Mar 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Vascular history: myocardial infarction (MI), unstable angina or coronary bypass surgery, stroke or transient ischemic attack (TIA), Peripheral Arterial Disease of the Lower Limbs (PAD), uncontrolled hypertension
- Need for analgesics for a cause other than migraine
- Difficulty in understanding French language or cognitive impairment that compromises completion of self-questionnaires.
Who the study is looking for
- Patients with Migraine \[International Headache Society (IHS) criteria 2013, revised 2018\] with or without aura
- Monthly number of attacks ≥ 8 for at least 3 months
- Indication for prophylactic treatment
- For eptinezumab: resistance to at least 2 conventional disease-modifying therapies
- Agrees to use data for research purposes
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHR Metz-Thionville/Hopital de Mercy Coordinator of this site? Confirm its status | Metz | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.